Oct 2022 Articles

Articles
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab
Schwartz G, Szarek M, Zeiher A, et al.
Journal:
J Am Coll Cardiol

First published: October 31, 2022 DOI: 10.1016/j.jacc.2022.09.035
View
- Share
Articles
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins
McQueen RB, Baum SJ, Louie MJ, et al.
Journal:
Am J Cardiovasc Drugs

First published: October 31, 2022 DOI: 10.1007/s40256-022-00552-7
View
- Share
Articles
Adherence to statin therapy – it seems we know everything, yet we do nothing…
Banach M, Penson PE
Journal:
European Heart Journal Open

First published: October 26, 2022 DOI: 10.1093/ehjopen/oeac071
View
- Share
Articles
Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study
Deshotels MR, Sun C, Nambi V, et al.
Journal:
J Am Heart Assoc

First published: October 26, 2022 DOI: 10.1161/JAHA.122.026762
View
- Share
Articles
Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
Desai NR, Farbaniec M, Karalis DG
Journal:
Clin Cardiol

First published: October 20, 2022 DOI: 10.1002/clc.23935
View
- Share
Articles
Individualized therapy in statin intolerance: the key to success
Banach M, Cannon CP, Paneni F, et al.
Journal:
Eur Heart J

First published: October 18, 2022 DOI: 10.1093/eurheartj/ehac556
View
- Share
Articles
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees
Kronenberg F, Mora S, Stroes ESG
Journal:
Curr Opin Lipidol

First published: October 17, 2022 DOI: 10.1097/MOL.0000000000000855
View
- Share
Articles
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Nissen SE, Wolski K, Cho L, et al.
Journal:
Open Heart

First published: October 17, 2022 DOI: 10.1136/openhrt-2022-002060
View
- Share
Articles
EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials
Sheppard JP, Lakshmanan S, Dahal S, et al.
Journal:
JACC Cardiovasc Imaging

First published: October 15, 2022 DOI: 10.1016/j.jcmg.2022.04.014
View
- Share
Articles
World Heart Federation Cholesterol Roadmap 2022
Ray KK, Ference BA, Séverin T, et al.
Journal:
Global Heart

First published: October 14, 2022 DOI: 10.5334/gh.1154
View
- Share
Articles
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
Lacaze P, Bakshi A, Riaz M, et al.
Journal:
J Am Coll Cardiol

First published: October 4, 2022 DOI: 10.1016/j.jacc.2022.07.027
View
- Share
Articles
Lp(a): Are Antithrombotic Therapies the Key to Event Reduction?
Devesa A, Ibanez B, Fuster V
Journal:
J Am Coll Cardiol

First published: October 4, 2022 DOI: 10.1016/j.jacc.2022.08.722
View
- Share

1 2

Oct 2022 Articles

Articles

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

Schwartz G, Szarek M, Zeiher A, et al.

Articles

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

McQueen RB, Baum SJ, Louie MJ, et al.

Articles

Adherence to statin therapy – it seems we know everything, yet we do nothing…

Banach M, Penson PE

Articles

Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study

Deshotels MR, Sun C, Nambi V, et al.

Articles

Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease

Desai NR, Farbaniec M, Karalis DG

Articles

Individualized therapy in statin intolerance: the key to success

Banach M, Cannon CP, Paneni F, et al.

Articles

Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees

Kronenberg F, Mora S, Stroes ESG

Articles

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease

Nissen SE, Wolski K, Cho L, et al.

Articles

EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials

Sheppard JP, Lakshmanan S, Dahal S, et al.

Articles

World Heart Federation Cholesterol Roadmap 2022

Ray KK, Ference BA, Séverin T, et al.

Articles

Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes

Lacaze P, Bakshi A, Riaz M, et al.

Articles

Lp(a): Are Antithrombotic Therapies the Key to Event Reduction?

Devesa A, Ibanez B, Fuster V

Articles

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

Schwartz G, Szarek M, Zeiher A, et al.

Share

Articles

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

McQueen RB, Baum SJ, Louie MJ, et al.

Share

Articles

Adherence to statin therapy – it seems we know everything, yet we do nothing…

Banach M, Penson PE

Share

Articles

Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study

Deshotels MR, Sun C, Nambi V, et al.

Share

Articles

Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease

Desai NR, Farbaniec M, Karalis DG

Share

Articles

Individualized therapy in statin intolerance: the key to success

Banach M, Cannon CP, Paneni F, et al.

Share

Articles

Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees

Kronenberg F, Mora S, Stroes ESG

Share

Articles

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease

Nissen SE, Wolski K, Cho L, et al.

Share

Articles

EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials

Sheppard JP, Lakshmanan S, Dahal S, et al.

Share

Articles

World Heart Federation Cholesterol Roadmap 2022

Ray KK, Ference BA, Séverin T, et al.

Share

Articles

Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes

Lacaze P, Bakshi A, Riaz M, et al.

Share

Articles

Lp(a): Are Antithrombotic Therapies the Key to Event Reduction?

Devesa A, Ibanez B, Fuster V

Share